Filing Details
- Accession Number:
- 0001144204-14-042002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-07-08 21:00:44
- Reporting Period:
- 2014-07-03
- Filing Date:
- 2014-07-08
- Accepted Time:
- 2014-07-08 21:00:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1571320 | Paul Daniel Regan | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-07-03 | 1 | $37.69 | 1,411 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-07-03 | 1 | $250.00 | 1,410 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Disposition | 2014-07-03 | 1 | $0.00 | 1 | $37.69 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 109,999 | 2023-03-04 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2014.
- The remaining shares underlying this option vest on a pro rata monthly basis through March 4, 2017, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
Billionaire Hedge Funds
